SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Tyndall A, Fassas A, Passweg J, Ruiz de Elvira C, Attal M, Brooks P, et al, for the Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Autologous hematopoietic stem cell transplants for autoimmune disease—feasibility and transplant-related mortality. Bone Marrow Transplant 1999; 24: 72934.
  • 2
    Gratwohl A, Passweg J, Bocelli-Tyndall C, Fassas A, van Laar JM, Farge D, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005; 35: 86979.
  • 3
    Burt RK. BMT for severe autoimmune diseases: an idea whose time has come. Oncology 1997; 11: 10147.
  • 4
    Tyndall A. Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J Rheumatol Suppl 1997; 48: 947.
  • 5
    Oyama Y, Traynor E, Craig R, Barr W, Rosa R, Burt RK. Treatment related mortality (TRM) and overall mortality (OM) in patients undergoing autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases, a single center experience [abstract]. Blood 2003; 102: 986a.
  • 6
    Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, et al. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood 2005; 105: 297987.
  • 7
    Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A, et al. Effect of centre on outcome of bone marrow transplantation for acute leukemia. Lancet 2000; 355: 13936.
  • 8
    Burt RK, Fassas A, Snowden J, van Laar JM, Kozak T, Wulffraat NM, et al. Collection of hematopoietic stem cells from patients with autoimmune diseases. Bone Marrow Transplant 2001; 28: 112.
  • 9
    Bensinger WI. Should we purge? Bone Marrow Transplant 1998; 21: 1135.
  • 10
    Van der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 101334.
  • 11
    Burt RK, Slavin S, Burns W, Marmont A. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation. Blood 2002; 99: 76884.
  • 12
    Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 2005; 435: 60511.
  • 13
    Ermann J, Fathman C. Autoimmune diseases: genes, bugs and failed regulation. Nat Immunol 2002; 2: 75966.
  • 14
    Slavin S. Treatment of life threatening autoimmune diseases with myeloablative doses of immunosuppressive agents and autologous bone marrow transplantation: rationale and experimental background. Bone Marrow Transplant 1993; 12: 858.
  • 15
    Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998; 129: 10315.
  • 16
    Kasai M, Kiyama Y, Watanabe M, Seto K, Matsuura A, Tanaka J, et al. Toxicity of high-dose busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation. Transplant Proc 1992; 24: 152930.
  • 17
    Abratt RP, Morgan GW, Silvestri G, Willcox P. Pulmonary complications of radiation therapy. Clin Chest Med 2004; 25: 16777.
  • 18
    Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29: 33549.
  • 19
    Burt RK, Patel D, Thomas J, Yeager A, Traynor A, Heipe F, et al. The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis. Bone Marrow Transplant 2004; 34: 74551.
  • 20
    Tomei F, Papaleo B, Fantini S, Iavicoli S, Baccolo TP, Rosati MV. Vascular effects of occupational exposure to low-dose ionizing radiation. Am J Indust Med 1996; 30: 727.
  • 21
    Chun HG, Leyland-Jones BR, Caryk SM, Hoth DF. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep 1986; 70: 12258.
  • 22
    Moore J, Brooks P, Milliken S, Biggs J, Ma D, Handel M, et al. A pilot randomized trial comparing CD34-selected versus unmanipulated hemopoietic stem cell transplantation for severe, refractory rheumatoid arthritis. Arthritis Rheum 2002; 46: 23019.
  • 23
    Snowden JA, Passweg J, Moore JJ, Milliken S, Cannell P, van Laar J, et al. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. J Rheumatol 2004; 31: 4828.
  • 24
    Farge D, Henegar C, Carmagnat M, Daneshpouy M, Marjanovic Z, Rabian C, et al. Analysis of immune reconstitution after autologous bone marrow transplantation in systemic sclerosis. Arthritis Rheum 2005; 52: 155563.
  • 25
    Muraro PA, Douek DC, Packer A, Chung K, Guenaga FJ, Cassiani-Ingoni R, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 80516.
  • 26
    Sun W, Popat U, Hutton G, Zang YC, Krance R, Carrum G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004; 127: 9961008.
  • 27
    Traynor AE, Schroeder J, Rosa RM, Cheng D, Stefka J, Mujais S, et al. Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study. Lancet 2000; 356: 7017.
  • 28
    Thiel A, Alexander T, Schmidt CA, Hiepe F, Arnold R, Radbruch A, et al. Immune reconstitution after hematopoietic stem cell transplantation. In: BurtRK, MarmontAM, editors. Stem cell therapy for autoimmune disease. Georgetown (TX): Landes Biosciences; 2004. p. 20622.
  • 29
    Ponchel F, Verburg RJ, Bingham SJ, Brown AK, Moore J, Protheroe A, et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy induced lymphopenia. Arthritis Res Ther 2005; 7: R8092.
  • 30
    Verda L, Oyama Y, Craig R, Statkute L, Krosnjar N, Quigley K, et al. Restoration of the CD4+CD25 bright regulatory cell subset in patients with Crohn's disease following autologous non-myeloablative stem cell transplantation (NST) [abstract]. Blood 2005; 106: 619a.
  • 31
    De Kleer I, Vastert B, Klein M, Tehlenburg G, Arkesteijn G, Puga Yung G, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T-cells and restoring the CD4+CD25+ immune regulatory network. Blood 2006; 107: 1696702.
  • 32
    Bluestone JA, Tang Q. How do CD4+CD25+ regulatory T cells control autoimmunity? Curr Opin Immunol 2005; 17: 63842.
  • 33
    Jayne D, Passweg J, Marmont A, Farge D, Zhao X, Arnold R, et al. Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004; 13: 16876.
  • 34
    Burt RK, Traynor A, Statkute L, Barr WG, Rosa R, Schroeder J, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006; 295: 52735.
  • 35
    McSweeney PA, Nash RA, Sullivan KM, Storek J, Crofford RJ, Dansey R, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 160210.
  • 36
    McSweeney P, Furst D, Crofford L. High dose immunosuppressive therapy (HDIT) for severe systemic sclerosis (SSc): long term survivors show continued improvement of function and skin with stability in the lungs. Blood 2004; 104: 46a.
  • 37
    Binks M, Passweg JR, Furst D, McSweeney P, Sullivan K, Besenthal C, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 57784.
  • 38
    Farge D, Passweg J, van Laar JM, Marjanovic Z, Besenthal C, Finke J, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 97481.
  • 39
    Farge D, Marolleau JP, Zohar S, Marjanovic Z, Cabane J, Mounier N, et al. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicenter phase I-II study. Br J Haematol 2002; 119: 72639.
  • 40
    Oyama Y, Statkute L, Barr WG. Autologous non-myeloablative hematopoietic stem cell transplantation for diffuse scleroderma. Blood 2005; 106: 819a.
  • 41
    Tsukamoto H, Nagafuji K, Horiuchi T, Miyamoto T, Aoki K, Takase K, et al. Phase I-II trial of autologous peripheral blood stem cell transplantation in the treatment of refractory autoimmune disease. Ann Rheum Dis 2006; 65: 50814.
  • 42
    Marmont AM, Gualandi F, van Lint MT, Guastoni C, Bacigalupo A. Long term complete remission of severe nephrotic syndrome secondary to diffuse global lupus nephritis following autologous, haematopoietic peripheral stem (CD34+) cell transplantation. Lupus 2006; 14: 446.
  • 43
    Rosen O, Thiel A, Massenkeil G, Hiepe F, Haupl T, Radtke H, et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000; 2: 32736.
  • 44
    Traynor AE, Barr WG, Rosa RM, Rodriguez J, Oyama Y, Baker S, et al. Hematopoietic stem cell transplantation for severe and refractory lupus: analysis after five years and fifteen patients. Arthritis Rheum 2002; 46: 291723.
  • 45
    American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004; 50: 341826.
  • 46
    Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 44758.
  • 47
    Van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64: 1515.
  • 48
    White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 2000; 132: 94754.
  • 49
    Stratton RJ, Wilson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) 2001; 40: 848.
  • 50
    Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 51
    Law MP. Radiation-induced vascular injury and its relation to late effects in normal tissues. In: LettJT, AdlerH, editors. Advances in radiation biology. Vol. 9. New York: Academic Press; 1981. p. 3773.
  • 52
    Aref I, Cross P, Nair B. Case report: severe fibrosis in a patient with scleroderma and previous radiotherapy, a case report and literature review. Br J Radiol 1996; 69: 10556.
  • 53
    Delanian S, Maulard-Durdux C, Lefaix JL, Housset M. Major interactions between radiation therapy and systemic sclerosis: is there an optimal treatment? Eur J Cancer 1996; 32A: 7389.
  • 54
    Robertson JM, Clarke DH, Pevzner MM, Matter RC. Breast conservation therapy: severe breast fibrosis after radiation therapy in patients with collagen vascular disease. Cancer 1991; 68: 5028.
  • 55
    Varga J, Haustein UF, Creech RH, Dwyer JP, Jimenez SA. Exaggerated radiation-induced fibrosis in patients with systemic sclerosis. JAMA 1991; 265: 32925.
  • 56
    Chen AM, Obedian E, Haffty BG. Breast-conserving therapy in the setting of collagen vascular disease. Cancer J 2001; 7: 48091.
  • 57
    The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Mastectomy or lumpectomy? The choice of operation for clinical stages I and II breast cancer. CMAJ 1998; 158 Suppl 3: S1521.
  • 58
    O'Dell JR, Steigerwald JC, Kennaugh RC, Hawkins R, Holers VM, Kotzin BL. Lack of clinical benefit after treatment of systemic sclerosis with total lymphoid irradiation. J Rheumatol 1989; 16: 10504.
  • 59
    Scope A, Sadetzki S, Sidi Y, Barzilai A, Trau H, Kaufman B, et al. Breast cancer and scleroderma. Skinmed 2006; 5: 1824.
  • 60
    Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, et al. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2005; 62: 8604.